ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
1-Year Return
11.37%
This Quarter Return
+22.32%
1 Year Return
+11.37%
3 Year Return
+255.37%
5 Year Return
+558.9%
10 Year Return
+18,722.72%
AUM
$2.09B
AUM Growth
+$555M
(+36%)
Cap. Flow
+$412M
Cap. Flow
% of AUM
19.72%
Top 10 Holdings %
Top 10 Hldgs %
59.98%
Holding
59
New
13
Increased
21
Reduced
6
Closed
7
Top Buys
| 1 |
Puma Biotechnology
PBYI
|
+$56.2M |
| 2 |
ECYT
Endocyte, Inc. Common Stock
ECYT
|
+$51.8M |
| 3 |
Iovance Biotherapeutics
IOVA
|
+$47.7M |
| 4 |
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
|
+$45.2M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$42.3M |
Top Sells
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
+$57.9M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$28M |
| 3 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$16.8M |
| 4 |
CASC
Cascadian Therapeutics, Inc.
CASC
|
+$9.2M |
| 5 |
AGEN
Agenus
AGEN
|
+$8.17M |
Sector Composition
| 1 | Healthcare | 83.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Bristol-Myers Squibb
BMY
$96.8B
| – | – |
-456,223
| Closed | -$28M |
|
|
CLLS
52
Cellectis
CLLS
$299M
| – | – |
-78,289
| Closed | -$2.28M |
|
53
Incyte
INCY
$16.8B
| – | – |
-50,000
| Closed | -$4.74M |
|
54
MacroGenics
MGNX
$104M
| – | – |
0
| – | – |
|
55
SPDR S&P Biotech ETF
XBI
$5.52B
| – | – |
0
| – | – |
|
|
LUMO
56
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| – | – |
-88,379
| Closed | -$6.45M |
|
|
MYOK
57
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| – | – |
-398,207
| Closed | -$16.8M |
|
|
CASC
58
DELISTED
Cascadian Therapeutics, Inc.
CASC
| – | – |
-2,485,272
| Closed | -$9.2M |
|